Intrexon and Intrexon Health subsidiary Xogenex will present four abstracts as posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 1, 2019, between 5 - 6 pm ET in Columbia Hall at the Washington Hilton in Washington, D.C. Dr. Amit Patel (Founder of Xogenex) and Dr. Thomas Reed (Founder and CSO of Intrexon) will introduce scientific details associated with the development of INXN-4001, the world’s first triple effector gene drug candidate to treat heart failure currently in a Phase 1 trial.
The abstracts being presented are as follows:
- First Human Experience with Novel Triple Effector Gene Therapy for Heart Failure - INXN-4001 (Abstract Number 772)
- Retrograde Delivery of Novel Triple Effector pDNA Gene Therapy for Heart Failure (Abstract Number 775)
- Human Cardiac iPSC Evaluation of Novel Triple Effector Gene Therapy for Dilated Cardiomyopathy (Abstract Number 777)
- Minimally Invasive Novel Triple Effector Gene Therapy for Adriamycin Cardiomyopathy (Abstract Number 780)